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ABSTRACT
Objectives: The current study was undertaken to review and assess the medication usage pattern in patients with chronic kidney disease (CKD).
Methods: A 12-month prospective observational study was carried out at Shadan Teaching and General Hospital, Peerancheru (Hyderabad), 
involving 384 CKD patients considering the inclusion and exclusion criteria. Medication evaluation for optimization was done using the World Health 
Organization (WHO) core prescribing indicators. Data collected were entered using Microsoft Excel. Descriptive statistics such as mean, percentage, 
and standard deviation (SD) were used to present sociodemographic characteristics of the study participants.
Results: Out of the total of 384 patients, 249 (65%) were male and 135 (35%) were female with a mean age of 58.28 (SD: 13.12). A total of 384 
prescriptions were scrutinized with a total of 3634 drugs, out of which drugs acting on the cardiovascular system were the most prescribed drugs 
(36.37%). The average number of drugs per prescription was found to be 9.08 considering the total number of prescriptions. The percentage of 
drugs prescribed by generic name was 15.57%. The percentage of encounters with antibiotics was 25%, whereas the percentage of encounters with 
injections was 86%. The percentage of drugs prescribed from the Essential Drug List or Formulary was found to be 26.36%.
Conclusion: Assessment of medication usage patterns using the WHO core indicators in CKD patients helps to reinforce the current hospital guidelines 
for the optimal usage of medications. The introduction of a clinical pharmacist along with a multidisciplinary team provides intensive care to the 
patients and helps to improve the clinical outcome.
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INTRODUCTION
The kidneys are organs that serve a number of essential regulatory 
roles. Most of us know that our kidneys function as filters, removing 
metabolic wastes and toxins from the blood and excreting them through 
the urine. But the kidneys also serve other essential functions. Through 
various regulatory mechanisms, the kidneys help maintain the body’s 
water balance, electrolyte balance, and acid-base balance. Additionally, 
the kidneys produce or activate hormones that are involved in 
erythrogenesis, calcium metabolism, and the regulation of blood 
pressure and blood flow [1].
Due to the rise in the prevalence and incidence of chronic kidney disease 
(CKD), there is a major threat among the general population. It remains 
a mainstay problem throughout the world. Nearly 11–13% of CKD cases 
remain prevalent globally. As per the World Health Organization (WHO), 
the annual death rate of 850,000 contributed by this ailment [2].
Renal failure is a broad term mainly associated with the incompetency 
of kidneys to carry out their normal homeostatic and excretory function 
results in the accumulation of nitrogenous waste products in the body. 
It could be acute or chronic. CKD is characterized by the progressive 
morphological and physiological detrimental changes in the kidneys 
persistent for more than 3 months which is usually irreversible. Serum 
creatinine levels remain elevated for more than 3 months and estimated 
glomerular filtration rate is estimated to be <60 ml/min/m2 [3].
Medication usage pattern in CKD patient varies from patient to patient 
depending on the condition and duration of the chronicity. Hence, 
it is essential to analyze the medication usage pattern among CKD 
patients from time to time as they need to acquire the medications 
throughout their life. In India, CKD remains a major threat to the 
health-care system as well as the patient’s well-being. Conducting the 
drug utilization survey for chronic diseases helps to promote rational 
use of drugs [2].
In 2017, the total mortality rate because of CKD and cardiovascular 
disease attributed to impaired kidney function was estimated to be 
4.6%. The overall mortality rate raised by 41.5% from 1990 to 2017. 
Researchers also reported that diabetic kidney disease remains the 
apparent cause of CKD [4]. Since very limited studies are available in 
India on the prescribing trends among CKD patients, this study was 
carried out with the main focus on the medication usage pattern in 
the management of CKD patients and also to assess the prescription 
following the rational use.
METHODS
Study site
The study was conducted at Shadan Institute of Medical Sciences, 
Peerancheru, Hyderabad.
Study design
•	 Prospective observational study
•	 Review and collection of cases.
Study duration
The study was carried out for 12 months.
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Sample size
Approximately 384 patients were enrolled in the study who fulfilled the 
inclusion and exclusion criteria.
Inclusion criteria
The following criteria were included in the study:
1. All CKD patients
2. Both male and female patients
3. Patients with/without comorbid conditions
4. Patients with risk factors of CKD.
Exclusion criteria
The following criteria were excluded from the study:
1. Patients refused to participate in the study
2. Patients Who cognitive impairment
3. Pregnant and lactating women.
Research methodology
Medication evaluation for optimization was done using the WHO core 
prescribing indicators, that is,
•	 Average number of drugs per encounter
•	 Percentage of drugs prescribed by generic name
•	 Percentage of encounters with an antibiotic prescribed
•	 Percentage of encounters with an injection prescribed
•	 Percentage of drugs prescribed from the essential medicine list or 
formulary.
Study approval
Permission for collecting patient data was approved by the ethical 
committee of Shadan Hospital. It also permits the utilization of the 
hospital facilities for regular follow-ups of prescriptions for research 
work.
Statistical analysis
Data were checked for completeness, correctness, and grouped 
accordingly. Data collected were entered using Microsoft Excel. 
Descriptive statistics such as mean, percentage, and standard deviation 
(SD) were used to present sociodemographic characteristics of the 
study participants.
RESULTS
A total of 384 patients were included in the study considering inclusion 
and exclusion criteria. Out of total 384 patients, 249 (65%) were male 
and 135 (35%) were female. This study shows male predominance. 
Gender-wise distribution is summarized in Fig. 1.
Age-wise distribution of patients
In this study, age ranged from 21 to 84 years. The mean age of the 
population was 58.28 (SD: 13.12). The majority of the participants were 
in the age group >60 years (50%) of age. The age-wise distribution of 
patients is summarized in Fig. 2.
Sociodemographic characteristics of the study participants
Sociodemographic characteristics of the study participants were also 
analyzed. The relevant data are presented in Table 1.
Distribution based on comorbidities
Almost all the patients enrolled in the study had at least more than 
1 comorbid condition. Hypertension (HTN) (34.10%) is the most 
common comorbid condition which is followed by diabetes mellitus 
(DM) (20.30%), anemia (13.30%), and cardiovascular disorders 
(8.05%).
The distribution of comorbidities in CKD patients is enumerated in 
Fig. 3.
Medication usage pattern
A total of 384 prescriptions were scrutinized with a total of 3634 
drugs, out of which drugs acting on the cardiovascular system were the 
Table 1: Sociodemographic characteristics of the study 
participants
Variables Categories Frequency 
(n)
Percentage
20–40 years 42 11
Age (years) 41–60 years 150 39
>60 years 192 50
Sex Male 250 65
Female 134 35
Marital status Married 263 68.50
Single 121 31.50




Residence Urban 246 64
Rural 138 36
Occupation Retired 119 31
Private employee 77 20
Government employee 31 8
Business 36 9.50
Others 121 31.50
Social history Non-smokers 275 71.50
Smokers 109 28.50
Monthly income Low 29 7.50
Average 59 15.50
Above average 94 24.50
High 202 52.50
Duration of HTN <5 years 111 29
5–15 years 167 43.50
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GENDER WISE DISTRIBUTION OF CKD PATIENTS
Fig. 1: Gender-wise distribution
most prescribed drugs (1322 drugs, 36.37%) followed by vitamins and 
minerals (548 drugs, 15.07%), hematinics (426 drugs, 11.72%), and 
gastrointestinal drugs (334 drugs, 9.19%), whereas acid-base disorder 
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Table 2: Medication usage pattern in CKD patients
Drug class Frequency Percentage
Cardiovascular drugs (n=1322, 36.37%)
Calcium channel blockers 250 18.91
Diuretics 168 12.7
Centrally acting alpha agonist 90 6.80
Beta-blockers 194 14.67
Alpha-blockers 122 9.22
Anticoagulants and ant platelets 206 15.58
Hypolipidemics 114 8.62
Vasodilators 16 1.21




Epoetin alpha 204 47.88
IV iron sucrose 144 33.80
Darbepoetin 34 7.98
Oral elemental iron 18 4.22
Folate 26 6.10
Antidiabetic drugs (n=186, 5.11%)
Insulin 114 61.29
Oral hypoglycemic agents 72 38.70
Vitamins and minerals (n=548, 15.07%)
Calcium carbonate+Vitamin D3 156 28.46
Vitamin D3 derivatives 92 16.78
Vitamin B complex 94 17.15
Others 206 37.59
Gastrointestinal drugs (n=334, 9.19%)
Proton-pump inhibitors 200 59.88
Dopamine antagonist 10 2.99
H2 blockers 18 5.38
Others 106 31.73
Acid-base disorder drugs (n=30, 0.82%)
Sodium bicarbonate 14 46.66
Febuxostat 16 53.33
Phosphate binders (n=92, 2.53%)















Thyroid medications (n=62, 1.70%)
Levothyroxine 62 100
Drugs acting on nervous system (n=96, 2.64%)
CNS drugs 96 100
Miscellaneous drugs (n=208, 5.72%)
Others 208 100







PPI+Dopamine blockers 16 13.79
ARBs: Angiotensin receptor blockers, PPI: Proton-pump inhibitors,  
RAAS: Renin-angiotensin-aldosterone system, RASI: 







HTN DM THYROID MBD ANAEMIA PULMO CVS OTHERS
DISTRIBUTION BASED ON CO-MORBIDITIES
Fig. 3: Distribution based on comorbidities
drugs were least prescribed (30 drugs, 0.82%). The most commonly 
prescribed combination therapy was antiplatelets + hypolipidemics 
(42 drugs, 36.20%). A complete summary of the medication usage 
pattern among study participants is depicted in Table 2.
WHO core drug use indicator
In this current study, medication usage pattern was analyzed using 
the WHO core drug use indicators. A total of 3634 medicines were 
prescribed. Therefore, the average number of drugs per prescription 
was found to be 9.08 considering the total number of prescriptions. 
The percentage of drugs prescribed by generic name was 15.57%. 
The percentage of encounters with antibiotics was 25%, whereas 
percentage of encounters with injections was 86%. The percentage of 
drugs prescribed from the essential drug list or formulary was found 
to be 26.36%. A brief description of the WHO prescribing indicators is 
summarized in Table 3.
DISCUSSION
In this present study, out of 384 CKD patients, 65% were male 
whereas only 35% were female. This shows male predominance over 
females. Similar reports were published by various other authors. 
Shastry et al. [5] and Abhisek et al. [6] reported 75% and 71.3% of male 
dominance over the female.
This suggests that males are more prone to CKD when compared to 
females. This is mere because of different hormonal environments [7]. 
In this present study, the majority of the participants were in the age 
group >60 years (50%) of age. A similar observation where the majority 
of participants were the elderly in the age group above 60 years (54%) 
was made by Monika et al. [8].
The existence of several comorbid conditions leads to the requirement 
of multiple drug therapy to treat the underlying condition. The average 
number of drugs per prescription was found to be 9.08 considering the 
total number of prescriptions. Chakraborty et al. [9] and Al-Ramahi [10] 
reported that3almost similar results with an average number of drugs 
per prescription were 10 and 9.38, respectively.
Our study revealed that the percentage of drugs prescribed by 
generic name was found to be 15.57%. Similar studies were 
conducted by Shrestha and Dixit and Shastry et al. where the 
percentage of drugs prescribed by generic name was 16.94% 
and 8.7%, respectively [5,11]. Whereas, Ahlawat et al. and 
Bajait et al. reported none of the drugs prescribed with the generic 
name [12,13]. This revealed that prescribing with brand names 
remains a common practice in major parts of the world. Therefore, 
there is a need to encourage prescription writing by generic name 
to promote rational drug use.
This study revealed that the percentage of encounters with injections 
was 86%. Similar results were reported by Shrestha and Dixit which 
were 71% of encounters with injections [11]. Prescribing a large 
number of injections in CKD patients is normal due to the presence of 
comorbid conditions such as anemia and DM where parenteral use of 
erythropoietin and insulin is required for management.
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Table 3: WHO core drug indicator
Indicators Data
Prescribing indicators
Average number of drugs per prescription 9.08
Percentage of drugs prescribed by generic name 15.57%
Percentage of encounters with an antibiotics 25%
Percentage of encounters with injections 86%
Percentage of drugs prescribed from essential drug list 
or formulary
26.36%
In our study, the percentage of encounters with antibiotics was 25%. 
Our study results lie within the standard range (20.0–26.8%) which 
is considered to be ideal [14]. Whereas other studies show a slightly 
higher range such as the study conducted by Shrestha and Dixit and 
Ulhas and Rataboli who reported 64.1% and 31.8% of encounters with 
antibiotics, respectively [11,15].
In this current study, the percentage of drugs prescribed from the 
WHO essential drug list was found to be 26.36%. Similar studies were 
conducted by Ahlawat et al. and Sindhura et al. who showed 19% 
and 36.1% of drugs prescribed from the WHO essential drug list, 
respectively [12,16].
In this study, cardiovascular drugs were the most prescribed drugs 
(661 drugs, 36.37%) followed by vitamins and minerals (n=274, 
15.07%) and hematinics (n=213, 11.72%).Whereas, a study conducted 
by Monika et al. who reported that cardiovascular drugs (16.48%) 
are most frequently prescribed followed by gastrointestinal tract 
drugs (14.07%) and nutritional supplements (10.88%) [8]. Since the 
majority of the population suffers from the comorbid condition of HTN, 
cardiovascular drugs are mostly required for their management.
Among the cardiovascular drugs, calcium channel blockers (CCBs) were 
most commonly prescribed (18.91%) in our study. Similar results were 
reported by Shastry et al. [5], Bailie et al. [17], Dasari et al. [18], and 
Tadvi and Hussain [19] where CCBs were most commonly prescribed 
constituting 78.05%, 27.6%, 60.5%, and 52%, respectively . Where 
as studies conducted by Chakraborty et al. [9], Ahlawat et al. [12], 
and Bajait et al. [13] constituting 9.29%, 54%, 9.50% respectively 
followed by CCBs. In our study, nearly 80.05% of participants were 
at end-stage renal disease. Therefore, CCBs are being preferred over 
renin-angiotensin-aldosterone system inhibitors as this may aggravate 
hyperkalemia and also require dosage adjustment.
In our study, among phosphate binders (PBs), 93.47% of sevelamer was 
prescribed while only 6.52% of calcium acetate was prescribed. A study 
conducted by Martins et al. who reported the high use of sevelamer 
(45.4%) over other calcium-based PBs (26.5%) [20]. In contrast to 
the studies conducted by Chakraborty et al. (11.02%) [9] and Bajait 
et al. (9.97 %) [13] reported higher use of calcium-based PBs when 
compared to sevelamer due to high cost.
Sevelamer, a newer non-calcium, non-aluminum binder, is used more 
frequently to avoid soft-tissue calcification which is caused by calcium-
based PBs such as calcium acetate and calcium carbonate. Moreover, 
sevelamer is associated with a reduction of coronary and aortic 
calcification [13]. A recent meta-analysis reported that non-calcium-
based PBs associated with a 22% reduction in all-cause mortality 
compared to calcium-based PBs in CKD patients [21].
CONCLUSION
Assessment of medication usage patterns using the WHO core 
indicators in CKD patients helps to reinforce the current hospital 
guidelines for the optimal usage of medications. Due to the existence 
of comorbid conditions in CKD patients, polypharmacy remains the 
common practice in the clinical setting. Therefore, the likelihood 
for drug interactions and adverse outcomes are very common. The 
introduction of a clinical pharmacist along with a multidisciplinary 
team provides intensive care to the patients and helps to improve the 
clinical outcome. There is a need to encourage prescription writing in 
generic names to eliminate medication errors and need to enhance the 
medication use from the WHO essential drug list for the easy access to 
the cost-effective medication.
Further sophisticated studies with special emphasis on drug interaction, 
adverse events, pharmacoeconomics, and assessment tools for early 
detection of CKD need to be carried out.
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